Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cytokinetics, Incorporated - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
CYTK
Nasdaq
2834
www.cytokinetics.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cytokinetics, Incorporated
Cytokinetics Touts MYQORZO Launch Momentum, Plans New FDA Filing
- Nov 17th, 2026 2:12 am
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Nov 16th, 2026 2:00 pm
Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM
- Nov 16th, 2026 2:00 am
Cytokinetics’ MYQORZO Gains Ground as Company Plans Push Into New Heart-Disease Market
- Nov 16th, 2026 1:12 am
Mid-cap biotech catalysts: FDA dates, earnings, and pipeline data to watch
- Nov 9th, 2026 2:06 pm
Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026
- Nov 9th, 2026 5:30 am
FDA Decision Watch: Summit’s Lung Cancer Drug, Cytokinetics’ Heart Therapy And Teva’s Igalmi In Spotlight This Week
- Nov 9th, 2026 3:23 am
Cytokinetics' Myqorzo Could Inflect Revenue Starting 2027, RBC Capital Markets Says
- Nov 5th, 2026 10:18 am
Cytokinetics (CYTK) Q3 2026 Earnings Call Transcript
- Nov 5th, 2026 10:02 am
Cytokinetics, Incorporated Q3 2026 Earnings Call Summary
- Nov 5th, 2026 6:30 am
Cytokinetics (CYTK) Could Be 41% Undervalued Following Strong Q3 And Aficamten Data
- Nov 5th, 2026 3:11 am
How MYQORZO Adoption Will Impact Cytokinetics (CYTK) Stock
- Nov 4th, 2026 11:14 pm
Cytokinetics Inc (CYTK) (Q3 2026) Earnings Call Highlights: Micorzo Launch Surges with 76% ...
- Nov 4th, 2026 10:19 pm
Cytokinetics Q3 Earnings Call Highlights
- Nov 4th, 2026 7:14 pm
Cytokinetics (CYTK) Reports Q3 Loss, Beats Revenue Estimates
- Nov 4th, 2026 2:10 pm
Cytokinetics: Q3 Earnings Snapshot
- Nov 4th, 2026 2:06 pm
Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update
- Nov 4th, 2026 2:00 pm
Cytokinetics to Participate in November Investor Conferences
- Nov 3rd, 2026 2:00 pm
Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026
- Nov 2nd, 2026 5:30 am
Will Alector (ALEC) Report Negative Q3 Earnings? What You Should Know
- Oct 29th, 2026 7:00 am
Scroll